Compounded GLP-1 Research: the Trial That Does Not Exist (2026)

10 papers · each one re-checked on PubMed · last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Start with what is missing. There is no published head-to-head trial comparing compounded semaglutide or tirzepatide against the approved product, whether for bioequivalence, efficacy or safety. The gap is structural. Compounded drugs are prepared under exemptions that never required pre-market equivalence testing in the first place, unlike a generic, which must prove it matches. So anyone claiming compounded semaglutide is 'the same drug' is making a claim no study has tested, and anyone claiming it is dangerous is going beyond what these papers establish too. What the literature does contain is documentation: impurities identified by mass spectrometry, dosing errors severe enough to reach poison control, adverse-event signals on both sides of the Atlantic, and a market that frequently does not disclose what it is selling. Read them as evidence about manufacturing and market conduct, not as a verdict on equivalence.

Ranked papers

#1

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system

McCall KL, et al. · Expert Opin Drug Saf · 2026

What it measured: Whether compounded products drew unusual adverse-event reports in the FDA database

A pharmacovigilance analysis of FDA adverse-event reports from 2018 to 2024, comparing the 707 that involved compounded products with the rest of the 81,078 GLP-1 reports. Compounded products had higher reporting odds for preparation errors, prescribing errors, contamination and compounding or manufacturing problems, and for abdominal pain, diarrhea, nausea, suicidality and gallbladder inflammation. Their reports were also more likely to involve a hospital stay. Administration and dosing errors, by contrast, were reported less often than with the brands. Spontaneous reports have no denominator and cannot establish cause, so this identifies where to look rather than what is true.

PMID 40285721 ↗DOI 10.1080/14740338.2025.2499670 ↗

#2

A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications

Jordan B, et al. · Expert Opin Drug Saf · 2026

What it measured: Finding and measuring an unidentified impurity in compounded tirzepatide vials

The most consequential analytical paper here. Testing of mass-compounded tirzepatide-with-B12 products bought from various US sources found a widespread impurity that had not been identified before, present at substantial levels. It forms when tirzepatide reacts chemically with certain forms of B12, so it exists only because of the combination. Its clinical effects are unknown. This does not prove harm. It does establish that these products contain something the approved drug does not, and that nobody tested before selling them.

PMID 42010938 ↗DOI 10.1080/14740338.2026.2663185 ↗

#3

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs

Hach M, et al. · Pharm Res · 2024

What it measured: How compounded product compares chemically with the approved drug, including clumping

A laboratory comparison of 16 injectable and 8 oral semaglutide follow-on products and 2 liraglutide ones against the originator drugs. The injectable semaglutide copies carried new impurities, among them high-molecular-weight proteins, residual solvents and trace metals. Several oral products held markedly less semaglutide than their labels claimed, some sequences could provoke an immune response, and the liraglutide copies were less physically stable. The authors are careful here: they write that nobody knows yet whether these differences change how well or how safely the drug works, and that clinical studies should find out. What they show is that the manufacturing gap is real and measurable at molecular level.

PMID 39379664 ↗DOI 10.1007/s11095-024-03771-6 ↗

#4

Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance

Zinzi A, et al. · Front Pharmacol · 2026

What it measured: Whether counterfeit-flagged reports stood out in Europe's adverse-event database

The European counterpart, drawn from the EMA's pharmacovigilance database and isolating 234 reports from 2018 through 2025 where the semaglutide was potentially counterfeit. Almost 9 in 10 of the reactions were classed as serious, and low blood sugar, use for an unapproved purpose, malaise and 'drug ineffective' were all reported more often than with genuine semaglutide. Counterfeit and compounded are not the same category, and conflating them is a common error. Still, few analyses manage to separate non-genuine supply from the authentic background at all.

PMID 42137313 ↗DOI 10.3389/fphar.2026.1805842 ↗

#5

Administration errors of compounded semaglutide reported to a poison control center — Case series

Lambson JE, et al. · J Am Pharm Assoc (2003) · 2023

What it measured: Case-series description of compounded semaglutide dosing-error calls

The foundational clinical paper on how people actually get hurt, and it is not about chemistry. Three people who had bought compounded semaglutide from compounding pharmacies or an aesthetic spa called a regional poison center after dosing mistakes, two of them after injecting ten times their dose. Each had nausea, vomiting and abdominal pain, usually for days; one was treated with an antiemetic and IV fluids at a health care facility. One had been sent a vial and syringes with no counseling, and one measured doses in milliliters and units rather than milligrams. This is the hazard that distinguishes a compounded vial from a prefilled pen, and it is a delivery-format problem: a vial lacks the safety features that stop a pen user from drawing up a tenfold dose.

PMID 37392810 ↗DOI 10.1016/j.japh.2023.06.017 ↗

#6

Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study

McIntyre RS, et al. · Expert Opin Drug Saf · 2026

What it measured: Whether accidental overdose reports rose as compounded supply expanded

The national version of the case series above, drawn from the FDA's adverse-event database from late 2003 to early 2024. It found 3,348 reports of accidental overdose with GLP-1 drugs, and every drug in the class (semaglutide, dulaglutide, exenatide, liraglutide and tirzepatide) was reported for accidental overdose disproportionately often against a comparison drug, with reporting odds ratios from 2.64 to 61.12. The authors tie the pattern to people turning to online and compounding pharmacies when approved drugs are scarce or unaffordable. Because the analysis sorts reports by drug rather than by source, it cannot separate the part of the signal that comes from compounded supply, and like any reporting database it shows association, not cause.

PMID 39552465 ↗DOI 10.1080/14740338.2024.2430306 ↗

#7

Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association

Neumiller JJ, et al. · Diabetes Care · 2025

What it measured: A professional society's formal position on using compounded products

The American Diabetes Association's formal position, and the most authoritative US specialty guidance on this question. It recommends against using compounded GLP-1 and GIP/GLP-1 products that are not FDA-approved, because their content, safety, quality and effectiveness are uncertain. When an approved drug is unavailable, it advises switching to another FDA-approved medication and reassessing once supply returns. It cites reported dosing errors and adverse events with compounded products, and counterfeit products in the US supply chain.

PMID 39620926 ↗DOI 10.2337/dci24-0091 ↗

#8

Navigating compounded semaglutide: what health care providers need to know

Liu G, et al. · Am J Manag Care · 2025

What it measured: Practical guidance for a clinician asked about compounded semaglutide

A practical review written for the clinician who gets asked about this in a ten-minute appointment. It covers the shortage rule that allowed compounded copies, the salt forms some suppliers use, the dosing errors vials invite, fraudulent batches, and what a patient should be told, including how to check that a pharmacy is accredited. Read it alongside the ADA statement. The ADA advises against compounded products, while this review accepts lawful compounding and focuses on steering patients to safe sources.

PMID 40966636 ↗DOI 10.37765/ajmc.2025.89787 ↗

#9

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

DiStefano MJ, et al. · J Pharm Policy Pract · 2025

What it measured: What direct-to-consumer sellers in one state advertised and claimed about compounded GLP-1s

A cross-sectional pilot audit of the direct-to-consumer sellers themselves: 93 businesses advertising compounded GLP-1s for weight loss across 188 locations in Colorado, found by web search in spring 2024 and mostly medical spas or weight-loss services. 41 of the 93 invoked FDA approval when describing compounded products, 5 called them 'generic', and the offerings included unapproved combinations, one with BPC-157, a substance the FDA has found unsafe for compounding. This is the paper closest to what we do here: a market that often misdescribes what it is selling. No bioequivalence trial can capture that, and it determines what a buyer actually receives.

PMID 39776466 ↗DOI 10.1080/20523211.2024.2441220 ↗

#10

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities

Asbill HR, et al. · Int J Pharm Compd · 2026

What it measured: Which compounding pathway is the safer source for a hospital during a drug shortage

An ethics and regulatory analysis built around a hypothetical injectable, 'drug X', on the FDA shortage list, asking where a hospital system should source it. Its conclusion is that 503B outsourcing facilities are a safer source than 503A pharmacies: they make larger batches, answer to closer FDA supervision and are bound by current good manufacturing practice. It is useful background on why the two compounding pathways carry different quality guarantees.

PMID 42143782 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-10-30 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.